Dual orexin receptor antagonists (DORAs) prolong total sleep time (TST) and enhance sleep efficiency (SE) without impairing respiratory function among patients with obstructive sleep apnea (OSA).
Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.